BIOCRYST PHARMACEUTICALS, INC. Operating Lease, Payments
BIOCRYST PHARMACEUTICALS, INC. (BCRX) reported Operating Lease, Payments of $1.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-08-05
- BIOCRYST PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2026-06-30 was $778.00K, a 50.19% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2026-03-31 was $405.00K, a 5.19% increase year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2025-12-31 was $119.00K, a 72.00% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, payments for the quarter ending 2025-09-30 was $444.00K, a 31.38% decline year-over-year.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, payments for fiscal 2025 was $1.47M, a 32.00% decline from fiscal 2024.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, payments for fiscal 2024 was $2.16M, a 12.29% increase from fiscal 2023.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, payments for fiscal 2023 was $1.92M, a 23.47% increase from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. operating lease, payments for fiscal 2022 was $1.55M, a 4.36% increase from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 6 month as first filed | Operating Lease, Payments 9 month | Operating Lease, Payments 9 month as first filed | Operating Lease, Payments 12 month | Operating Lease, Payments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $778.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.18M 10-Q · filed 2026-08-05 | $1.30M derived: sum of 3 quarters · filed 2026-08-05 | $1.75M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $405.00K 10-Q · filed 2026-05-06 | $524.00K derived: sum of 2 quarters · filed 2026-05-06 | $968.00K derived: sum of 3 quarters · filed 2026-05-06 | $1.49M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $119.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $563.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.08M derived: sum of 3 quarters · filed 2026-08-05 | $1.47M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $444.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $962.00K derived: sum of 2 quarters · filed 2026-08-05 | $1.35M 10-Q · filed 2025-11-04 | $1.77M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $518.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $903.00K 10-Q · filed 2026-08-05 | $1.33M derived: sum of 3 quarters · filed 2026-08-05 | $1.98M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $385.00K 10-Q · filed 2026-05-06 | $810.00K derived: sum of 2 quarters · filed 2026-05-06 | $1.46M derived: sum of 3 quarters · filed 2026-05-06 | $2.02M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $425.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.07M derived: sum of 2 quarters · filed 2026-02-26 | $1.63M derived: sum of 3 quarters · filed 2026-02-26 | $2.16M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $647.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $1.21M derived: sum of 2 quarters · filed 2025-11-04 | $1.73M 10-Q · filed 2025-11-04 | $2.27M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $559.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $1.08M 10-Q · filed 2025-08-05 | $1.63M derived: sum of 3 quarters · filed 2026-02-26 | $2.46M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $525.00K 10-Q · filed 2025-05-06 | $1.07M derived: sum of 2 quarters · filed 2026-02-26 | $1.90M derived: sum of 3 quarters · filed 2026-02-26 | $2.65M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $544.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.38M derived: sum of 2 quarters · filed 2026-02-26 | $2.12M derived: sum of 3 quarters · filed 2026-02-26 | $1.92M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $834.00K 10-Q · filed 2023-11-08 | $1.58M derived: sum of 2 quarters · filed 2023-11-08 | $1.38M 10-Q · filed 2024-11-05 | $2.29M 10-Q · filed 2023-11-08 | $1.76M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-06-30 | $746.00K 10-Q · filed 2023-08-07 | $874.00K 10-Q · filed 2024-08-06 | $1.45M 10-Q · filed 2023-08-07 | $928.00K derived: sum of 3 quarters · filed 2025-02-25 | $1.54M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2023-03-31 | $423.00K 10-Q · filed 2024-05-07 | $705.00K 10-Q · filed 2023-05-08 | $182.00K derived: sum of 2 quarters · filed 2025-02-25 | $797.00K derived: sum of 3 quarters · filed 2025-02-25 | $1.40M derived: sum of 4 quarters · filed 2025-02-25 | |||
| 2022-12-31 | -$241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $374.00K derived: sum of 2 quarters · filed 2025-02-25 | $981.00K derived: sum of 3 quarters · filed 2025-02-25 | $1.55M 10-K · filed 2025-02-25 | $2.45M 10-K · filed 2023-02-27 | |||
| 2022-09-30 | $615.00K 10-Q · filed 2023-11-08 | $1.22M derived: sum of 2 quarters · filed 2023-11-08 | $1.80M 10-Q · filed 2023-11-08 | $2.16M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-06-30 | $607.00K 10-Q · filed 2023-08-07 | $1.18M 10-Q · filed 2023-08-07 | $1.55M derived: sum of 3 quarters · filed 2024-02-27 | $1.85M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2022-03-31 | $574.00K 10-Q · filed 2023-05-08 | $939.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.25M derived: sum of 3 quarters · filed 2024-02-27 | $1.62M derived: sum of 4 quarters · filed 2024-02-27 | ||||
| 2021-12-31 | $365.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $671.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.05M derived: sum of 3 quarters · filed 2024-02-27 | $1.49M 10-K · filed 2024-02-27 | $1.61M 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $306.00K 10-Q · filed 2022-11-04 | $685.00K derived: sum of 2 quarters · filed 2022-11-04 | $1.13M 10-Q · filed 2022-11-04 | $1.59M derived: sum of 4 quarters · filed 2022-11-04 | ||||
| 2021-06-30 | $379.00K 10-Q · filed 2022-08-05 | $819.00K 10-Q · filed 2022-08-05 | $1.28M derived: sum of 3 quarters · filed 2022-08-05 | $1.67M derived: sum of 4 quarters · filed 2022-08-05 | ||||
| 2021-03-31 | $440.00K 10-Q · filed 2022-05-09 | $901.00K derived: sum of 2 quarters · filed 2022-05-09 | $1.29M derived: sum of 3 quarters · filed 2022-05-09 | $1.73M derived: sum of 4 quarters · filed 2022-05-09 | ||||
| 2020-12-31 | $461.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $855.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.29M derived: sum of 3 quarters · filed 2022-02-28 | $1.70M 10-K · filed 2022-02-28 | ||||
| 2020-09-30 | $394.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $827.00K derived: sum of 2 quarters · filed 2021-11-04 | $1.24M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | $433.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $841.00K 10-Q · filed 2021-08-09 | ||||||
| 2020-03-31 | $408.00K 10-Q · filed 2021-05-07 | |||||||
| 2019-12-31 | $1.46M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |